Dong-A ST Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1932-01-01
- Employees
- 1.6K
- Market Cap
- -
- Website
- http://www.donga-st.com
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 27
- Registration Number
- NCT02963389
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 265
- Registration Number
- NCT02955706
- Locations
- 🇰🇷
Konkuk university medical center, Seoul, Korea, Republic of
Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT02954822
- Locations
- 🇰🇷
Clinical Trials Center, Seoul National University Hospital, Seoul, Korea, Republic of
Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 222
- Registration Number
- NCT02949193
- Locations
- 🇰🇷
Kangbuk Samsung Medical Center, Seoul, Korea, Republic of
A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT02946541
- Locations
- 🇰🇷
Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of
Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT02824380
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy Subjects
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT02821312
Study to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 119
- Registration Number
- NCT02780323
- Locations
- 🇰🇷
Kyung Hee University Hospital, Seoul, Korea, Republic of
Efficacy and Safety of DA-3002 in Short Children Borns SGA.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT02770157
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg
Phase 1
Completed
- Conditions
- Interventions
- Drug: Evogliptin, Pioglitazone, Evogliptin+PioglitazoneDrug: Pioglitazone, Evogliptin, Evogliptin+PioglitazoneDrug: Evogliptin, Evogliptin+Pioglitazone, PioglitazoneDrug: Pioglitazone, Evogliptin+Pioglitazone, EvogliptinDrug: Evogliptin+Pioglitazone, Evogliptin, PioglitazoneDrug: Evogliptin+Pioglitazone, Pioglitazone, Evogliptin
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT02753803
- Locations
- 🇰🇷
Clinical Trials Center, Seoul National University Hospital, Seoul, Korea, Republic of
© Copyright 2024. All Rights Reserved by MedPath